Virax Holdings advances new prospects for Co-X-Gene anti-cancer technology
Virax Holdings (ASX:VHL)
has finalised the review process on its Co-X-Gene™ anti-cancer
technology, conducted by Easington Pty Ltd of Melbourne as a
professional independent expert.
The review outlined the
potential further applications of the Co-X-Gene™ platform, and will
allow formulation of strategic plans and explore further collaboration
opportunities.
The strength of the technology was confirmed
recently by licensing partner Transgene, demonstrating topline results
for their Phase 2B clinical trial using Co-X-Gene, conducted under an
option with Novartis (NYSE:NVS), in the treatment of Non-Small Cell Lung Cell Cancer.
Novartis is the largest pharmaceutical company in the world with a
capitalisation of almost $200 billion, and Transgene’s immunotherapeutic
product TG4010, utilizes Virax's Co-X-Gene platform.
Transgene’s
activities have now also gained the interest of major pharmaceutical
company Sanofi (NYSE:SNY) capitalised at over $130 billion.
Sanofi
and Transgene have subsequently launched construction of a
manufacturing platform for the production of viral vectors, as utilized
by Transgene’s immunotherapeutic product.
The Company’s planned
development pipeline moving forward is to appoint an expert in gene
technology to assist in identifying various new opportunities.
These
include medical conditions outside of cancer, potential biomarkers for
pre-selecting tailored patient groups, intellectual property
considerations, and potential veterinary applications.
VHL also intends to convene a Scientific Advisory Board, and apply for non-diluting funding grants.
Related news
- Yellow Diamonds - A Gap in the Diamond market
- Coffee with Samso: Episode 1, Australian Tungsten Projects and How the Chinese Market View The Tungsten sector
- Chasing for Kryptonite, the unknown other Lithium source
- What is In-Situ Recovery? Mining in a National Park with no environmental footprint
- Buds & Duds: Cannabis stocks drop but Weekend Unlimited shares jump on CBD hemp seed news
- Hemispherx treats first patient with cancer drug Ampligen in Phase 2 clinical trials
- THC Global granted cannabis Manufacture Licence, shares surge 20%
.jpg)